These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32015437)

  • 21. CRISPR Tools for Engineering Prokaryotic Systems: Recent Advances and New Applications.
    Burbano DA; Kiattisewee C; Karanjia AV; Cardiff RAL; Faulkner ID; Sugianto W; Carothers JM
    Annu Rev Chem Biomol Eng; 2024 Jul; 15(1):389-430. PubMed ID: 38598861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The discovery and development of the CRISPR system in applications in genome manipulation.
    Lau V; Davie JR
    Biochem Cell Biol; 2017 Apr; 95(2):203-210. PubMed ID: 28103055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR-Based Gene Drives for Pest Control.
    McFarlane GR; Whitelaw CBA; Lillico SG
    Trends Biotechnol; 2018 Feb; 36(2):130-133. PubMed ID: 29221716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional Features and Current Applications of the RNA-Targeting Type VI CRISPR-Cas Systems.
    Perčulija V; Lin J; Zhang B; Ouyang S
    Adv Sci (Weinh); 2021 Jul; 8(13):2004685. PubMed ID: 34254038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells.
    Guo J; Gong L; Yu H; Li M; An Q; Liu Z; Fan S; Yang C; Zhao D; Han J; Xiang H
    Nat Commun; 2024 Aug; 15(1):7277. PubMed ID: 39179566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR deactivation in mammalian cells using photocleavable guide RNAs.
    Zou RS; Liu Y; Ha T
    STAR Protoc; 2021 Dec; 2(4):100909. PubMed ID: 34746867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dead Cas Systems: Types, Principles, and Applications.
    Brezgin S; Kostyusheva A; Kostyushev D; Chulanov V
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
    Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
    Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic and diagnostic relevance of Crispr technology.
    El Ouar I; Djekoun A
    Biomed Pharmacother; 2021 Jun; 138():111487. PubMed ID: 33774312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 Technology in Translational Biomedicine.
    Leonova EI; Gainetdinov RR
    Cell Physiol Biochem; 2020 Apr; 54(3):354-370. PubMed ID: 32298553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A catalogue of biochemically diverse CRISPR-Cas9 orthologs.
    Gasiunas G; Young JK; Karvelis T; Kazlauskas D; Urbaitis T; Jasnauskaite M; Grusyte MM; Paulraj S; Wang PH; Hou Z; Dooley SK; Cigan M; Alarcon C; Chilcoat ND; Bigelyte G; Curcuru JL; Mabuchi M; Sun Z; Fuchs RT; Schildkraut E; Weigele PR; Jack WE; Robb GB; Venclovas Č; Siksnys V
    Nat Commun; 2020 Nov; 11(1):5512. PubMed ID: 33139742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo.
    Aryal NK; Wasylishen AR; Lozano G
    Cell Death Dis; 2018 Oct; 9(11):1099. PubMed ID: 30368519
    [No Abstract]   [Full Text] [Related]  

  • 34. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving CRISPR Genome Editing by Engineering Guide RNAs.
    Moon SB; Kim DY; Ko JH; Kim JS; Kim YS
    Trends Biotechnol; 2019 Aug; 37(8):870-881. PubMed ID: 30846198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations.
    Wang J; Zhang C; Feng B
    J Cell Mol Med; 2020 Mar; 24(6):3256-3270. PubMed ID: 32037739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fusion guide RNAs for orthogonal gene manipulation with Cas9 and Cpf1.
    Kweon J; Jang AH; Kim DE; Yang JW; Yoon M; Rim Shin H; Kim JS; Kim Y
    Nat Commun; 2017 Nov; 8(1):1723. PubMed ID: 29167440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure and engineering of Brevibacillus laterosporus Cas9.
    Nakane T; Nakagawa R; Ishiguro S; Okazaki S; Mori H; Shuto Y; Yamashita K; Yachie N; Nishimasu H; Nureki O
    Commun Biol; 2024 Jul; 7(1):803. PubMed ID: 38961195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Versatile 3' Functionalization of CRISPR Single Guide RNA.
    Palumbo CM; Gutierrez-Bujari JM; O'Geen H; Segal DJ; Beal PA
    Chembiochem; 2020 Jun; 21(11):1633-1640. PubMed ID: 31943634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.